Tuis2AB • FRA
add
Barinthus Biotherapeutics PLC - ADR
Vorige sluiting
€0,90
Dagwisseling
€0,82 - €0,82
Jaarwisseling
€0,76 - €3,24
Markkapitalisasie
35,93 m USD
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 14,97 m | — |
Bedryfskoste | 23,72 m | 49,31% |
Netto inkomste | -8,11 m | 42,34% |
Netto winsgrens | -54,21 | — |
Wins per aandeel | -0,21 | 43,24% |
EBITDA | -8,48 m | 41,43% |
Effektiewe belastingkoers | 0,04% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 106,10 m | -33,81% |
Totale bates | 188,69 m | -17,95% |
Totale aanspreeklikheid | 29,23 m | -14,95% |
Totale ekwiteit | 159,46 m | — |
Uitstaande aandele | 40,23 m | — |
Prys om te bespreek | 0,22 | — |
Opbrengs op bates | -12,19% | — |
Opbrengs op kapitaal | -13,40% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -8,11 m | 42,34% |
Kontant van bedrywe | -18,20 m | -62,61% |
Kontant van beleggings | -114,00 k | -216,67% |
Kontant van finansiering | 465,00 k | 910,87% |
Netto kontantverandering | -11,67 m | 8,25% |
Beskikbare kontantvloei | -18,26 m | -1 948,34% |
Meer oor
Barinthus Biotherapeutics plc is a biotechnology company developing immunotherapies for infectious diseases, cancer and autoimmune diseases such as hepatitis B, HPV and prostate cancer. Formerly known as Vaccitech plc, in November 2023 the company announced that it had renamed itself to Barinthus Biotherapeutics plc. As of 2024, the company employs more than 100 people. Wikipedia
Gestig
2016
Webwerf
Werknemers
130
